News Hub | News Direct

All Industries

Article thumbnail News Release


DPH Biologicals

DPH Biologicals, a leading developer and supplier of agricultural biologicals, has launched Envelix TM Prime, a patented, biological nutrient enhancer designed to uniformly cover bulk dry fertilizer, delivering a robust biological consortium paired with fertilizer in a single application. “Envelix Prime enables both retailers and growers to seamlessly unlock the value of biologicals on a broader scale,” said Mick Messman, DPH Bio President & CEO. “Just one pound of Envelix Prime evenly covers a ton of dry fertilizer, giving retailers a way to differentiate their fertilizer blends with biology while giving growers a single-purchase, single application route to enhanced performance and an increased return on their fertilizer investment.” Envelix Prime contains naturally occurring beneficial bacterial and fungal microorganisms designed to accelerate and maximize fertility release using a patented carrier to adhere microorganisms to the fertilizer prill. In a tissue sample taken from a 2023 corn trial at the V3 leaf stage, Envelix Prime increased nutrient uptake of several macro and micronutrients when applied to MESZ fertilizer, including: An 18% increase in phosphorus, A 10% increase in sulfur. A 9% increase in boron. An 8% increase in copper. Envelix Prime is DPH Bio’s first product to be powered by Prime™, a one-of-a-kind, patented spore priming technology that germinates beneficial bacteria faster, and in harsher conditions, enabling more consistent biological performance. In a recent corn trial, Prime enabled more than 70% of spores to germinate at temperatures as high as 98.6 degrees, while those without Prime germinated less than 10%. Additionally, nearly all spores with Prime germinated in high salt environments, while those that were not treated with Prime did not germinate. Envelix Prime mixes seamlessly with MAP, DAP & Urea, offering improved flowability and less bridging at application. “We are excited to get Envelix Prime out on the broad acre this fall enabling many growers the opportunity to experience the benefits of biologicals for the first time. This integrated approach requires no change in practice for the grower and, with the addition of Prime, we are confident that growers will consistently see the benefits this dynamic product unlocks both in the field and to their bottom line,” said Messman. Envelix Prime is available now to retail partners and fertilizer blending facilities. For more information about DPH Bio’s technology platforms – RegenAphex™ and Prime, as well as DPH Bio’s expanded product portfolio, visit About DPH Biologicals DPH Biologicals, LLC attracts, develops and scales technologies improving broad market access and simplifying the grower experience with biologicals. Based on investments in scientific research, field testing, partner relationships and product development, and leadership-owned since 2024, DPH Bio yields success through science and relationships, standing at the leading edge of clarity, trust and proven, profitable solutions for agricultural biologicals. For more information, visit Contact Details AgTech PR for DPH Biologicals Jennifer Goldston Company Website

June 12, 2024 08:30 AM Eastern Daylight Time

Article thumbnail News Release Issues Comprehensive Evaluation of MediaCo Holding Inc

MediaCo Holding Inc

NEW YORK, NY / News Direct/ June 12th, 2024 / Best Growth Stocks, a leading independent equity research and corporate access firm focused on finding and reporting on the best growth stocks utilizing exclusive ai-assisted research recently issued a comprehensive evaluation of MediaCo Holding Inc. a publicly listed media company that super-serves communities throughout the country. MediaCo Holding Inc (NASDAQ: MDIA) has recently caught the attention of many investors following an acquisition of all of Estrella Media’s network, content, digital, and commercial operations. Among the Estrella Media brands that have joined MediaCo are the EstrellaTV network and its influential linear and digital video content business, and Estrella Media’s expansive digital channels, including its four FAST channels – EstrellaTV, Estrella News, Cine EstrellaTV, and Estrella Games – and the EstrellaTV app. The transaction closed on April 17, 2024. Best Growth Stock's full report breaks through the noise and offers a comprehensive analysis of MediaCo’s operations, Estrella Media’s operations, financials, share structure, chart setup, potential catalysts, recent business combination, and much more. Access this full analysis free: (If you cannot click the link above, copy and paste to your browser may be required) Access this full analysis free: (If you cannot click the link above, copy and paste to your browser may be required) About MediaCo MediaCo Holding Inc. (“MediaCo”) is a publicly listed media company (NASDAQ: MDIA) that super-serves communities throughout the country. MediaCo owns and operates two iconic radio stations in New York City, HOT 97 (WQHT-FM) and WBLS-FM, which boast extensive digital reach across the US. The company primarily generates revenue from advertising sales, program syndication and live events. To learn more about MediaCo, visit About Best Growth Stocks Best Growth Stocks is a leading independent equity research and corporate access firm focused on finding and reporting on the best growth stocks utilizing our exclusive ai-assisted research. BGS is also a financial news provider, focused on giving investors direct access to CEOs of promising, publicly-traded companies, and market experts. Our CEO interviews aim to answer the questions that rest on the minds of current and future shareholders. This is not to be construed as financial advice. Please consult with a licensed financial advisor before making any investment decisions. Contact Details Best Growth Stocks Steve Macalbry

June 12, 2024 08:30 AM Eastern Daylight Time

Article thumbnail News Release

JasmyCoin Holders Jump to Raboo Presale Amid Dogecoin's Rising Wave

Total Media

Dogecoin and JasmyCoin price share different trajectories while still offering good trading opportunities. The current Dogecoin forecast is bullish, while JasmyCoin price action continues to sizzle. However, one new contender has emerged in the form of AI/SocialFi meme coin presale sensation Raboo, which analysts can go on a 100x tear in 2024. Read up to find out why experts predict Raboo could outperform even the most bullish JasmyCoin price prediction, and Dogecoin forecast this year. New contenders coming for Dogecoin’s crown Dogecoin lays claim to being the OG meme coin, creating the blueprint for every single meme coin within the $57.6 billion sector. Dogecoin has come a long way from being an ironic take on the “wild west” era of the crypto world, growing to a $20 billion market cap. Early Dogecoin investors have made millions of times over their initial investments, especially those that sold at Dogecoin’s all-time high of $0.73 back in 2021. Today, Dogecoin serves as an “index” for the meme coin market. However, the current Dogecoin forecast is bearish due to its large market cap, which severely restricts its growth potential. The Dogecoin forecast for 2024 is one of limited gains, with more capital flowing into lower-cap opportunities that have larger room to grow. The most bullish Dogecoin forecast predicts a 3x to 5x gain for the token should the next bull run materialize. JasmyCoin price prediction for 2024 looking up JasmyCoin has turned in almost a 950% YTD figure as of press time, firmly outdoing the Dogecoin forecast within the same 12-month period. Here’s the cool thing about JasmyCoin: despite the 10x growth in the past year, The current JasmyCoin price is still 99.2% from its February 2021 all-time high of $4.99, indicating a potentially limitless growth trajectory. That is, of course, if JasmyCoin bulls continue pushing prices as they have over the past year. If they manage to do so, JasmyCoin could outperform the Dogecoin forecast for 2024. However, JasmyCoin has a $1.78 billion market cap, with early holders selling off in favor of projects like Raboo. Raboo presale surges into Stage 4 with a 60% rally Crypto presales offer a can’t-miss buying opportunity, considering it is during this phase when token prices are going to be as low as they possibly can be. Especially meme coins with an innovative utility like Raboo. Finding presale opportunities with the potential for 100x gains like Raboo can be a needle in a haystack. But now, prospective investors could get in on a low-cap blue chip at a price of just $0.0048. Raboo is a meme coin featuring AI-powered SocialFi utility. Using Rabooscan, the platform’s AI-enabled meme generator, users can create memes and NFTs designed to engage the Raboo community and grow it by attracting new joiners by disseminating them through social media. In doing so, users can earn Raboo tokens in exchange for their efforts. With the meme coin market sitting at a $58 billion market cap—with limitless growth potential in 2024 and beyond—Raboo is a rare opportunity to get in on a legitimate 100x moon shot set to outperform both Dogecoin forecast and JasmyCoin price this year. Raboo users can also stake their $RABT tokens or provide liquidity for passive income, and its deflationary tokenomics ensures a constantly stable price with the potential to skyrocket in price at any given time. Conclusion With token prices available at just $0.0048, Raboo blows JasmyCoin and Dogecoin out of the water as far as upside potential in 2024 is concerned. Don’t miss out on an opportunity to get in on the ground floor of a project that could go all the way to the top this year—join the Raboo presale today. You can participate in the Raboo presale here. Telegram: Twitter: Contact Details Total Media Solutions

June 12, 2024 06:30 AM Eastern Daylight Time

Article thumbnail News Release

Therma Bright’s Investment Case Just Got Stronger As Approval On Permanent Insurance Codes Gets Closer


Therma Bright (TSXV:THRM) (OTCQB:TBRIF), a developer of a wide range of leading edge, proprietary diagnostic and medical device technologies that address some of today's most important medical and healthcare challenges, appears to be positioned for major growth based on one important upcoming catalyst. For some background, Therma Bright (TSXV:THRM) (OTCQB:TBRIF) sells Venowave, a compact, battery operated peristaltic pump that generates a wave-form motion. When worn below the knee and strapped to the calf, the resulting compression of the calf causes an increased upward volumetric displacement of venous and lymph fluid. The Venowave is FDA approved for 10 indications, including: Management of Post Thrombotic Syndrome, Prevention of Deep Vein Thrombosis (DVT / blood clots), treatment of Chronic Venous Insufficiency, as well as other conditions related to poor circulation in the extremities.It seems that the company is set to receive a newly issued, HCPCS Level II code to identify it’s Venowave device,which will be instrumental in driving revenue growth. HCPCS codes are a set of health care procedure codes used in the United States to standardize the reporting of medical procedures, services and devices. These codes are essential for billing and reimbursement purposes within the Medicare and Medicaid programs, and are also used by other healthcare insurers in the United States, including private insurance companies. Additionally, a preliminary Medicare Payment determination will be made for this new HCPCS code. If the Venowave is purchased outright, Medicare and Medicaid will reimburse $1,199 USD. If the unit is rented to the patient, Medicare and Medicaid will pay $78.05 USD / month for up to 13 months, for a total of $819.55 USD. These are very favourable numbers for Therma Bright when taking into account the manufacturing cost of Venowave. Additionally, private insurers such as blue cross blue shield, UnitedHealth Group, etc., also use these codes as guidelines to determine reimbursement payouts. Why is this so important? Previously, Venowave was placed into the E0676 HCPCS code. E0676 is a miscellaneous code with no set reimbursement, meaning that when Venowave is billed for under this code, Medicare and Medicaid, as well as private insurance companies will default to a $0 reimbursement. While it is possible to submit a package of medical necessity under this code, with a detailed explanation of the patients’ condition and why it should be reimbursed, the reality is that most physicians or prescribing parties will not go through this exercise as they are not reimbursed for the time and trouble it takes. Therma Bright experienced a similar situation with the temporary codes it was approved to sell Venowave under in 2023 – Without the prescribing party submitting a package of medical necessity, Venowave by default will not be paid for. Additionally, these reimbursement issues are a barrier to prescribing parties recommending Venowave, as they are not able to tell their patients if the device will be paid for. Physicians tend to shy away from prescribing devices in these categories, as they could leave their patient with a large unexpected medical bill, reflecting badly on the prescribing party. This new HCPCS code combined with the preliminary payment determination establishes a fixed payout for Venowave across public and private insurers in the United States, eliminating friction in payments as well as hesitancy by the prescribing parties in recommending the device. Therma Bright expects to receive this new HCPCS code and payment determination after the biannual CMS meeting which was held at the end of May, 2024. Venowave differentiates itself from other available compression products in a number of ways. Currently, pneumatic devices and simple products that squeeze the leg make up the majority of the compression market. Inexpensive portable compression devices simply squeeze and release the calf, and do not actively move fluid upwards towards the heart. Sequential compression devices are proven very effective, however they are not portable. Sequential compression devices have tubes attached to an air compressor which inflates chambers in sequence, providing sequential compression. Typically these devices can only be used while lying in bed, on a couch or in a similar position, and do not allow the patient to remain ambulatory. Venowave combines the best of both worlds, providing sequential compression without the use of tubes or wires, allowing the patient to remain completely ambulatory while receiving treatment. Additionally, Venowave is quiet, so patients can continue to receive treatment while they are sleeping or otherwise resting. Currently in the United States an estimated 25 million people are living with some form of Chronic Venous insufficiency. Most go untreated or rely on simple compression stockings for some form of minor relief, as proper treatment via sequential compression devices is too cumbersome and expensive. The issuance of this new HCPCS code and payment determination opens up these patients to the Venowave, a new and portable form of treatment that will not cost them anything out of pocket. This market alone, along with the management of Post Thrombotic Syndrome and prevention of primary thrombosis is potentially huge. Additionally, Therma Bright is working towards securing reimbursement for DVT prevention. While Medicare and Medicaid do not pay for DVT prevention, private insurers do. Therma Bright is confident that the issuance of this new HCPCS code and payment determination will help patients access Venowave for DVT prevention via their private health insurance, which is another huge addressable market in the United States. During the last year, Therma Bright has been meeting with potential distributors across the United States. Many have indicated interest in the Venowave pursuant to a positive outcome with regards to the HCPCS coding. Therma Bright currently has over 2000 Venowave units in inventory, which they expect can be moved right away upon the issuance of the HCPCS code. After these initial 2000 units are sent to distributors, placed on patients, and reimbursement received, Therma Bright conservatively estimates moving 500-1000 units / month. Given the high margin on Venowave, this will fare well for the company. As Venowave is a high margin product, the company is looking at the possibility of setting up a manufacturing operation in either the U.S, Canada or Mexico which would allow it to sell to the VA in the US. This would open up yet another large market for Venowave in the United States. For investors who may be interested in Therma Bright, it is important to note that Venowave isn’t its only product. The company also has respiratory health and consumer health product portfolios. The respiratory health product portfolio features the Digital Cough Test (DCT) app created by Therma Bright (TSXV:THRM) (OTCQB:TBRIF) and AI4LYF. The app uses artificial intelligence to detect multiple respiratory diseases by analyzing a person’s cough sound and has shown a high accuracy rate. The app is currently in the process of securing a 513g FDA clearance, which will allow the company to charge for Remote Therapeutic Monitoring (RTM) and be used for patient reimbursement. The consumer health product portfolio features devices designed for pain relief, cold sore prevention and insect bite relief. Disclaimers: RazorPitch Inc. "RazorPitch" is not operated by a licensed broker, a dealer, or a registered investment adviser. This content is for informational purposes only and is not intended to be investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled. RazorPitch has been retained and expects to be compensated by Therma Brite to assist in the production and distribution of content related to TBRIF. RazorPitch is responsible for the production and distribution of this content. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. This content is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained in this article constitutes a solicitation, recommendation, endorsement, or offer by RazorPitch or any third party service provider to buy or sell any securities or other financial instruments. All content in this article is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. RazorPitch is not a fiduciary by virtue of any persons use of or access to this content. Contact Details RazorPitch Inc Mark McKelvie +1 585-301-7700 Company Website

June 12, 2024 06:00 AM Eastern Daylight Time

Article thumbnail News Release

The Diverse Holdings of the Industrial ETF XLI

Select Sector SPDR

The Industrial Select Sector SPDR Fund ( XLI ) offers an investment opportunity within the dynamics of the industrial sector. XLI follows an index of industrial sector stocks within the S&P 500, weighted by modified market capitalization. With assets under management exceeding $18 billion, it boasts a low annual expense ratio of 0.09%*, offering an efficient and accessible route to the industrial sector. The top 10 holdings & weightings** for XLI: Starting with GE Aerospace at 4.75%, followed by Caterpillar at 4.55%, RTX Corporation at 3.78%, Union Pacific at 3.75%, Honeywell International at 3.52%, Eaton at 3.51%, Uber Technologies at 3.51%, Boeing at 2.69%, Lockheed Martin at 2.67%, and Automatic Data Processing at 2.66%. XLI ETF Industry and Sector Overview The variety of related industries are represented in the burgeoning industrial sector. Aerospace & Defense: The XLI ETF includes prominent companies within the aerospace and defense sector, positioning investors to have access to companies in this industry. Electrical Equipment Manufacturers: The fund's holdings feature leading electrical equipment manufacturers with their technological advancements and innovations within this sector. Construction & Engineering Firms: XLI provides exposure to renowned construction and engineering firms, allowing investors to tap into the ongoing infrastructure development and urbanization trends. Industrial Machinery Companies: The ETF also encompasses key players in the industrial machinery segment, enabling investors to participate in the machinery and equipment manufacturing landscape. Building Products: XLI encompasses a diverse range of building product companies, offering exposure to the construction and real estate market dynamics. As the industrial landscape continues to evolve, XLI emerges as a compelling choice for investors seeking exposure to the dynamic industrial sector. DISCLAIMER: This is a work of research and should not be taken as investment or financial advice. Therefore, Select Sector SPDRs or the publisher is not liable for any decision made based on the publication. About the Company: Select Sector SPDR ETFs offer flexibility and customization opportunities. Many investors have similar outlooks, but no two are exactly alike. Select Sector SPDR ETFs let investors select the sectors that best meet their investment goals. *Ordinary brokerage fees apply **Holdings, Weightings & Assets as of 5/31/24 subject to change DISCLOSURES The S&P 500 Index is an unmanaged index of 500 common stocks that is generally considered representative of the U.S. stock market. The index is heavily weighted toward stocks with large market capitalizations and represents approximately two-thirds of the total market value of all domestic common stocks. The S&P 500 Index figures do not reflect any fees, expenses or taxes. An investor should consider investment objectives, risks, fees and expenses before investing. One may not invest directly in an index. Transparent ETFs provide daily disclosure of portfolio holdings and weightings All ETFs are subject to risk, including loss of principal. Sector ETF products are also subject to sector risk and non-diversification risk, which generally will result in greater price fluctuations than the overall market. Diversification does not eliminate risk. An investor should consider investment objectives, risks, charges and expenses carefully before investing. To obtain a prospectus, which contains this and other information, call 1-866-SECTOR-ETF (732-8673) or visit Read the prospectus carefully before investing. ALPS Portfolio Solutions Distributor, Inc., a registered broker-dealer, is distributor for the Select Sector SPDR Trust. Media Contact: Company: Select Sector SPDRs Contact: Dan Dolan* Address: 1290 Broadway, Suite 1000, Denver, CO 80203 Country: United States Email: Website: *Dan Dolan is a Registered Representative of ALPS Portfolio Solutions Distributor, Inc. ALPS Portfolio Solutions Distributor, Inc., a registered broker-dealer, is the distributor for the Select Sector SPDR Trust. SEL007585 EXP 8/31/24 Contact Details Dan Dolan +1 203-935-8103 Company Website

June 12, 2024 05:00 AM Eastern Daylight Time

Article thumbnail News Release

AGC Biologics & Chief Executive Officer Patricio Massera Announce Plans for Him to Step Down

AGC Biologics

AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced that its Chief Executive Officer (CEO), Patricio Massera, will be stepping down from his role effective June 30. Patricio Massera joined the company in 2012, as General Manager of the Copenhagen site at CMC Biologics A/S. He later served as Chief Operating Officer of CMC Biologics at its Seattle headquarters. He held the same role after CMC Biologics was acquired by AGC Inc. and formed AGC Biologics. Mr. Massera was appointed CEO in 2019. He also served as an Executive Officer of the AGC Life Science Company, the Life Science Division of AGC Inc. During his tenure as CEO, Mr. Massera spearheaded several initiatives that elevated AGC Biologics' global business and brand. His work and achievements include key milestones such as navigating the COVID-19 pandemic, acquiring Molecular Medicine S.p.A. (“MolMed”) in Milan to create AGC Biologics’ Global Cell and Gene business, and acquiring facilities in Boulder and Longmont, Colorado to establish new large-scale commercial mammalian capacity and cell and gene services in North America. Mr. Massera also directed the company’s long-standing commitment to investing in single-use technology to ensure AGC Biologics could address the evolving needs of pharmaceutical companies using any platform process to develop new drug candidates. “Over the past 12 years, I have had the privilege of experiencing the most vibrant and remarkable professional position of my life. CMC Biologics, and later AGC Biologics, have provided me with countless opportunities. I have met incredible individuals driven by the desire to build a better world, all sharing the common purpose of enabling our partners to cure life-threatening diseases and bring hope to life.” Massera said. “During this journey, we have managed to grow the business multiple times. However, like all great stories, every book has an end. In this case, it is just a chapter that finishes. AGC Biologics has a long and brilliant journey ahead, but it is time for someone else to write the next chapter.” The new CEO search process is underway. In light of this transition, AGC Biologics is pleased to share Tadashi Murano, President of the AGC Life Science Company, will serve as interim CEO. He brings several decades of experience in global leadership roles within AGC Inc. across various business entities. For more information on AGC Biologics, visit About AGC Biologics: AGC Biologics is a leading global biopharmaceutical Contract Development and Manufacturing Organization (CDMO) with a strong commitment to delivering the highest standard of service as we work side-by-side with our clients and partners, every step of the way. We provide world-class development and manufacture of mammalian and microbial-based therapeutic proteins, plasmid DNA (pDNA), messenger RNA (mRNA), viral vectors, and genetically engineered cells. Our global network spans the U.S., Europe, and Asia, with cGMP-compliant facilities in Seattle, Washington; Boulder and Longmont, Colorado; Copenhagen, Denmark; Heidelberg, Germany; Milan, Italy; and Chiba, Japan. We currently employ more than 2,500 Team Members worldwide. Our commitment to continuous innovation fosters the technical creativity to solve our clients’ most complex challenges, including specialization in fast-track projects and rare diseases. AGC Biologics is a part of AGC Inc.’s Life Science Company. The Life Science company runs more than 10 global facilities focused on biopharmaceuticals, advanced therapies, small molecule active pharmaceutical ingredients, and agrochemicals. To learn more, visit Contact Details Nick McDonald +1 425-419-3555 Company Website

June 12, 2024 12:00 AM Pacific Daylight Time

Article thumbnail News Release

Benchmark International Successfully Facilitated the Transaction Between Tygra Industries, LLC and Fugue Capital

Benchmark International

Benchmark is pleased to announce the transaction between Tygra Industries, LLC and Fugue Capital. The transaction represents a strategic expansion for Fugue Capital as they work to achieve scale through acquisitions. Tygra Industries, LLC, also known as Tri-Tex Cabinets, is a custom cabinetry manufacturer specializing in residential kitchen, bathroom, closet, office, and mud and laundry room installations. Founded in 1967 by the Dane family, Tri-Tex Cabinets was acquired by Tygra Industries, LLC in 2015. Since then, the company has experienced continued success and growth. Fugue Capital, a private equity firm, focuses on energy, construction, professional services, and agriculture companies in Texas and surrounding regions. Fugue Capital prides itself on its industry experience, strategic initiatives, and ability to help companies in the lower middle market continue to grow and expand. "It was exciting to walk with our client through the different conversations, offers, and questions that had arisen regarding their opportunity. Our team enjoyed watching both Fugue Capital and Tygra Industries explore the mutual synergies they shared and the working relationship that has been formed between both parties to allow Fugue Capital to run the next race. We wish both parties the best of luck in their future endeavors." - Managing Director, Amy Alonso, Benchmark International Americas: Sam Smoot at +1 (813) 898 2350 / Europe: Michael Lawrie at +44 (0) 161 359 4400 / Africa: Anthony McCardle at +27 21 300 2055 / ABOUT BENCHMARK INTERNATIONAL: Benchmark International is a global M&A firm that provides business owners with creative, value-maximizing solutions for growing and exiting their businesses. Benchmark International has handled over $11 billion in transaction value across various industries from offices across the world. With decades of M&A experience, Benchmark International’s transaction teams have assisted business owners with achieving their objectives and ensuring the continued growth of their businesses. The firm has also been named the Investment Banking Firm of the Year by The M&A Advisor and the Global M&A Network as well as the #1 Sell-side Exclusive Privately-held M&A Advisor in the World by Pitchbook and Refinitiv's Global League Tables. Contact Details Brittney Zoeller +1 813-898-2350 Company Website

June 11, 2024 04:32 PM Eastern Daylight Time

Article thumbnail News Release

Lava Cake is the top cannabis strain on the market, new poll finds


Lava Cake is the cannabis strain whose effects are most popular with consumers, according to new consumer polling and analysis conducted by NuggMD, the leading telehealth platform for cannabis. The poll asked cannabis users their main goal for using cannabis, desired flavor/aroma, and desired effect. More than 6,500 randomized cannabis users responded. As a representative sample of all U.S. cannabis consumers, the poll’s margin of error is 1.2%. The top preferences respondents cited were: the goal of pain relief (25%), anxiety relief (23%), and stress relief (18%); a flavor profile of fruit (27%), sweetness (19%), and earthiness (18%); and the effects of relaxation (30%) and euphoria (24%). The full poll results are available here. The company then used its database of cannabis strains to identify popular strains that fit those preferences. While strains like Georgia Pie, Cheetah Piss, Mendo Breath, and GMO Cookies rank highly, Lava Cake is the only strain that meets all of those preferences, suggesting it is both the most durable strain on the market and the one that offers the most effects that consumers want. The poll also finds nearly half of all cannabis users hit it whenever they feel like it—the poll asked respondents when they prefer to consume cannabis, with a plurality, 48 percent, saying “anytime.” “Since the onset of the Covid-19 pandemic, Americans have become much more stressed out and anxious than previous generations, and I don’t think it’s a coincidence to see everyday Americans doing whatever they can to manage it all,” said Deb Tharp, head of legal and policy research at NuggMD. “Our polling data suggests that more Americans are using cannabis to mentally and emotionally handle the world around them than to escape from it.” used first-party data to conduct this poll. It was a questionnaire sent via email to a random list of opt-in respondents, all of whom consume cannabis regularly. The poll was conducted in May 2024. The sample contained no NuggMD customers. About NuggMD NuggMD is the nation’s leading medical marijuana technology platform, serving patients in Arizona, California, Connecticut, Delaware, Florida, Georgia, Illinois, Iowa, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Missouri, Montana, Nevada, New Jersey, New Mexico, New York, Ohio, Oklahoma, Pennsylvania, Texas, Vermont, Virginia, Washington, and West Virginia. They’ve connected over 1,300,000 patients face-to-face with their new medical marijuana doctors via their state-of-the-art telemedicine platform. They believe every human being has the right to explore the potential benefits of medical cannabis and are fully committed to helping each patient explore every option in their journey to wellness. For further information, visit Contact Details Andrew Graham +1 646-385-0189 Company Website

June 11, 2024 03:47 PM Eastern Daylight Time

Article thumbnail News Release

Legendary House of Bacha Coffee Establishes New Era of Coffee Appreciation

Bacha Coffee

Legendary brand Bacha Coffee enchants coffee drinkers with an exceptional collection of over 200 coffees from 35 of the most consistent and well renowned coffee producing countries around the globe. Renowned for elevating a daily commodity into an extraordinary experience, and revolutionizing the practice of coffee gifting, Bacha Coffee invites you to embark on a sensorial expedition with their selection of loose coffee beans sold by weight, coffee gift boxes, the innovative Coffee Bag collection, gift boxes, coffee accessories and more - all available through their online boutique, Bacha Coffee traces its origins back to 1910 and the Dar el Bacha, a palace hidden in the heart of the old city in Marrakech, Morocco. Nestled behind the millennia-old walls, a coffee room beckoned, shrouded in whispers of secrecy and graced by the likes of President Franklin D. Roosevelt, UK Prime Minister Winston Churchill, filmmaker Charlie Chaplin, entertainer Josephine Baker and other cultural and political names of the day. Uniting over glittering pots of “coffee of Arabica”, the Bacha Coffee room offered an escape and was a secret oasis known for its style and beauty, but above all, for its coffee. A Passion for Craftsmanship Today, driven by a fervent commitment to excellence and a deep reverence for the art of coffee making, Bacha Coffee is dedicated to preserving the timeless traditions of coffee craftsmanship while embracing innovation to meet the evolving tastes of modern coffee connoisseurs. Bacha Coffee offers a collection of more than 200 meticulously sourced Single-Origin, Fine Blended, Fine Flavoured, and naturally CO₂ Decaffeinated 100% Arabica coffees sourced from 35 countries around the world including Africa, the Arabian Peninsula, Central and South America, the Caribbean, Asia, and beyond. Bacha Coffee’s expertly trained Coffee Masters work with farmers to gather the best and freshest beans and then process them according to age-old traditional methods. Since each variety of coffee requires a different degree of roasting to bring out its unique taste profile, Bacha Coffee Masters hand-roast each harvest individually before gently air cooling them for the best taste and preservation. By sourcing coffee beans from diverse origins, Bacha Coffee celebrates the unique terroir and flavour characteristics of each region, offering customers an authentic taste that makes it a true haven for coffee lovers. Spoilt for Choice Discover the luxury of choice and 100% Arabica in every cup. The coffees available on mirror the extensive list offered in their original boutique in Marrakech and around the world, and invite coffee lovers to venture beyond the familiar to try harvests from unique farms and provenance. Bacha Coffee’s retail selection includes loose beans as well as beautifully packaged coffees and single serve coffee bags. Loose beans can be purchased by weight and ground to the specifications of each customer, from 7 different grind sizes. Consider the sought-after single origin Yirgacheffe Heirloom Coffee, a rare Ethiopian harvest that takes centre stage in the history of coffee. Grown at altitudes of over 6,500 feet above sea level, this unique varietal feature delicate notes of cane sugar, lemongrass, and bergamot. Combining two of the finest coffees in the world, Happy Arabia Coffee is a fine blended coffee that features a delicate acidity and rich flavours of red fruits, chocolate, and caramel. Fans of fine flavoured coffees may indulge in the 1910 Coffee, with aromas of freshly picked wild strawberries and jugs of cream perfect for a balmy summer’s day. Back to “Slow” Coffee What if we finally took the time to enjoy our coffee? Bacha Coffee allows you to indulge your senses by making the perfect, “slow” coffee at home or on the go, without the fuss. Explore over 30 Single Origin and Fine Flavoured coffees in the brand’s exclusive Coffee Bag Collection – individually wrapped, air tight, single-serve pour over coffee bags containing 12g of 100% Arabica each, expertly dosed to ensure a perfectly prepared brew so you only need 3 minutes, a coffee mug and hot water at hand to achieve the perfect pour over. The Explorer Taster box allows you to begin your journey, with a selection of single origin and fine flavoured coffee favourites. A Bespoke Gift Bacha Coffee’s series of elegant accessories and gourmet delights will elevate any coffee brewing, hosting, or drinking ritual. The exclusive, special edition Bacha Coffee x Alessi La Conica Espresso Coffee Pot pays homage to the heritage of Bacha Coffee and the tradition of Italian design and adds a touch of elegance to any table. Bacha Coffee’s selection of gourmet treats, such as Chocolate Covered Coffee Beans, will delight on any occasion. To share the love of coffee, explore artfully curated gift boxes or design your own bespoke hamper according to five sizes and assortments. Each gift includes complimentary gift wrap and a personalised note on Bacha Coffee’s signature gift card and envelope. A World of Discovery The Bacha Coffee online boutique ships internationally to over 40 countries and Bacha Coffees are distributed in luxury hotels, restaurants, and airlines worldwide. Bacha Coffee currently has 22 boutiques across ten countries and regions in Europe, Asia, North Africa, and the Middle East. Discover the world of Bacha Coffee and full range of products via A full press kit with visuals may be accessed here. All credits for images belong to Bacha Coffee. No royalties payable if Bacha Coffee is stated as the source. Additional images are available on request. About Bacha Coffee: Bacha Coffee was founded in Marrakech, Morocco in 1910 in the spectacular Dar el Bacha palace, where the greatest cultural and political minds of the century gathered over glittering pots of freshly brewed Arabica coffee. The original Marrakech location reopened in 2019 and launched its first international outpost in Singapore in the same year. With unique and exclusive Coffee Rooms & Boutiques, Coffee Bars, Travel Retail, and Takeaway concepts, Bacha Coffee has since expanded exponentially across Asia, the Middle East and Europe. Today, Bacha Coffee serves customers in over 40 countries, including online at Renowned for its legendary 100% Arabica coffees, gifts and coffee accessories, the Bacha Coffee concept also incorporates international distribution and wholesale to professionals. Contact Details Rell Marketing Linsey Tilbor Rubin +1 732-991-5294 Company Website

June 11, 2024 02:44 PM Eastern Daylight Time

1 ... 45678 ... 3613